📊 KNSA Key Takeaways
Is KNSA a Good Investment? Thesis Analysis
Kiniksa demonstrates excellent financial health with zero debt, exceptional free cash flow generation (20.1% margin), and strong liquidity, but concerning complete stagnation in revenue and earnings growth signals a mature or challenged product portfolio. The company prioritizes shareholder returns through buybacks over organic growth investment, suggesting limited growth catalysts despite fortress-like balance sheet fundamentals.
Why Buy KNSA? Key Strengths
- Zero long-term debt with $567.6M stockholders' equity and $165.6M cash provides exceptional financial flexibility
- Outstanding free cash flow generation of $136.4M (20.1% FCF margin) with minimal capex requirements demonstrates cash cow characteristics
- Superior liquidity position with 3.79x current ratio and 3.39x quick ratio ensures strong short-term financial stability
KNSA Investment Risks to Consider
- Flat revenue and net income growth (0.0% YoY) in pharmaceutical sector indicates stalled commercial performance and potential product maturity/decline
- Minimal capital expenditure of only $1.6M suggests underinvestment in R&D and future product pipeline, limiting long-term competitiveness
- Net margin of 8.7% and operating margin of 11.4% are modest for pharmaceuticals, indicating pricing pressure or high operating costs relative to revenue generation
Key Metrics to Watch
- Revenue growth trajectory and pipeline advancement - critical to assess whether stagnation is temporary or structural
- Operating cash flow sustainability and capital allocation decisions - monitor if cash is reinvested in R&D or returned to shareholders
- Product portfolio composition and patent expiration schedule - essential to evaluate revenue durability and competitive positioning
KNSA Financial Metrics
💡 AI Analyst Insight
The 20.1% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 3.79x current ratio provides a solid financial cushion.
KNSA Profitability Ratios
KNSA vs Healthcare Sector
How Kiniksa Pharmaceuticals International, plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KNSA Overvalued or Undervalued?
Based on fundamental analysis, Kiniksa Pharmaceuticals International, plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KNSA Balance Sheet & Liquidity
KNSA 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kiniksa Pharmaceuticals International, plc's revenue has grown significantly by 1,658% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.20 reflects profitable operations.
KNSA Growth Metrics (YoY)
KNSA Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $112.2M | -$3.9M | $-0.18 |
| Q2 2025 | $108.6M | -$3.9M | $-0.06 |
| Q1 2025 | $79.9M | $8.5M | $0.11 |
| Q3 2024 | $67.0M | -$3.9M | $-0.16 |
| Q2 2024 | $71.5M | $2.7M | $0.04 |
| Q1 2024 | $48.3M | -$12.3M | $-0.18 |
| Q3 2023 | $67.0M | -$11.2M | $-0.16 |
| Q2 2023 | $27.0M | $2.7M | $0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KNSA Capital Allocation
KNSA SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kiniksa Pharmaceuticals International, plc (CIK: 0001730430)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080406.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080407.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080403.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080454.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080439.xml | View → |
❓ Frequently Asked Questions about KNSA
What is the AI rating for KNSA?
Kiniksa Pharmaceuticals International, plc (KNSA) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KNSA's key strengths?
Claude: Zero long-term debt with $567.6M stockholders' equity and $165.6M cash provides exceptional financial flexibility. Outstanding free cash flow generation of $136.4M (20.1% FCF margin) with minimal capex requirements demonstrates cash cow characteristics.
What are the risks of investing in KNSA?
Claude: Flat revenue and net income growth (0.0% YoY) in pharmaceutical sector indicates stalled commercial performance and potential product maturity/decline. Minimal capital expenditure of only $1.6M suggests underinvestment in R&D and future product pipeline, limiting long-term competitiveness.
What is KNSA's revenue and growth?
Kiniksa Pharmaceuticals International, plc reported revenue of $677.6M.
Does KNSA pay dividends?
Kiniksa Pharmaceuticals International, plc does not currently pay dividends.
Where can I find KNSA SEC filings?
Official SEC filings for Kiniksa Pharmaceuticals International, plc (CIK: 0001730430) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KNSA's EPS?
Kiniksa Pharmaceuticals International, plc has a diluted EPS of $0.75.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KNSA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kiniksa Pharmaceuticals International, plc has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KNSA stock overvalued or undervalued?
Valuation metrics for KNSA: ROE of 10.4% (sector avg: 15%), net margin of 8.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KNSA stock in 2026?
Our dual AI analysis gives Kiniksa Pharmaceuticals International, plc a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KNSA's free cash flow?
Kiniksa Pharmaceuticals International, plc's operating cash flow is $138.0M, with capital expenditures of $1.6M. FCF margin is 20.1%.
How does KNSA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.7% (avg: 12%), ROE 10.4% (avg: 15%), current ratio 3.79 (avg: 2).